Literature DB >> 9926094

Pindolol augmentation of antidepressant therapy.

R McAskill1, S Mir, D Taylor.   

Abstract

BACKGROUND: Antidepressant therapy is not always effective and is slow to take effect. In theory, these shortfalls may be caused by induction of neuronal negative feedback via pre-synaptic 5-HTIA receptors. Pindolol, an antagonist at somatodentritic pre-synaptic 5-HTIA receptors has been investigated as a potential accelerator and augmentor of antidepressant response.
METHOD: A Medline search was conducted in November 1997.
RESULTS: Six open-label studies and six controlled studies were identified for review.
CONCLUSIONS: Open-label studies strongly suggest that pindolol may accelerate and augment antidepressant response, but controlled studies do not wholly support these findings: only three of six studies clearly demonstrate benefit. Larger, well-designed, controlled trials are needed to determine definitively the effectiveness of pindolol in this context.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9926094     DOI: 10.1192/bjp.173.3.203

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  15 in total

Review 1.  Pharmacological treatment of depression. Consulting with Dr Oscar.

Authors:  M J Berber
Journal:  Can Fam Physician       Date:  1999-11       Impact factor: 3.275

Review 2.  Fortnightly review: drug treatment of depression.

Authors:  O Spigset; B Mårtensson
Journal:  BMJ       Date:  1999-05-01

3.  SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue.

Authors:  J Watson; C Roberts; C Scott; I Kendall; L Collin; N C Day; M H Harries; E Soffin; C H Davies; A D Randall; T Heightman; L Gaster; P Wyman; C Parker; G W Price; D N Middlemiss
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

4.  Medicine Cabinet: Drug treatment of depression.

Authors:  B Martensson; O Spigset
Journal:  West J Med       Date:  1999-08

Review 5.  The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency?

Authors:  G G Kinney; M T Taber; V K Gribkoff
Journal:  Mol Neurobiol       Date:  2000-06       Impact factor: 5.590

6.  Effects of (-)-tertatolol, (-)-penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study.

Authors:  S E Gartside; E M Clifford; P J Cowen; T Sharp
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 7.  Serotonin 1A and Serotonin 4 Receptors: Essential Mediators of the Neurogenic and Behavioral Actions of Antidepressants.

Authors:  Benjamin Adam Samuels; Indira Mendez-David; Charlène Faye; Sylvain André David; Kerri A Pierz; Alain M Gardier; René Hen; Denis J David
Journal:  Neuroscientist       Date:  2014-12-08       Impact factor: 7.519

8.  Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats.

Authors:  Athina Markou; Amanda A Harrison; Jessica Chevrette; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

9.  Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories.

Authors:  Athina Markou; Paul J Kenny
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

10.  Repeated administration of the 5-HT(1B) receptor antagonist SB-224289 blocks the desensitisation of 5-HT(1B) autoreceptors induced by fluoxetine in rat frontal cortex.

Authors:  Galit Shalom; Eitan Gur; Louis D Van de Kar; Michael E Newman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.